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Abstract
Background: The aim of this study was to determine whether intrahepatic cholestasis of pregnancy (ICP) is
associated with causes of death during on average 35 years follow-up after the delivery.
Methods: The study population comprised 571 women with ICP in at least one pregnancy seen at Tampere University
Hospital, Finland, between 1969 and 1988. ICP was verified from patient records. The previous and following subjects in
the maternity ward diary were taken as controls for each ICP case. In total, there were 1333 controls. All underlying
causes of death were obtained from Statistics Finland in March 2017. The deaths occurred during 1971–2015 and the
causes of death were classified according to ICD-10.
Results: Altogether, 39 of the mothers with ICP (6.8%) and 111 of the controls (8.3%) had died by the end of 2015
(p = 0.267). There were more underlying causes of death from gastrointestinal diseases (15%) in the ICP group than in
the control group (4%) (p = 0.011). The number of underlying causes of death due to diseases of the circulatory system
were lower in the ICP group (13%) than in the control group (26%), although the finding was not statistically significant
(p = 0.088). Moreover, neoplasms were the underlying cause of death in 46% of cases among mothers with ICP and in
41% of cases among the controls (p = 0.609). Diseases of the other organ systems were rare in both groups.
Conclusion: Women with a history of ICP do not have an increased overall mortality. However, deaths from
gastrointestinal diseases are overrepresented among women with a history of ICP.
Keywords: Intrahepatic cholestasis of pregnancy, Causes of death, Mortality
Background
Intrahepatic cholestasis of pregnancy (ICP) is a revers-
ible liver dysfunction during pregnancy. It is character-
ized by otherwise unexplained pruritus, especially on the
palms of the hands, soles of the feet, and the abdomen.
The diagnosis also requires a rise in serum bile acids
and transaminases [1]. ICP is associated with perinatal
complications, for example meconium staining of the
amniotic fluid, stillbirth and preterm delivery [2, 3].
Ursodeoxycholic acid is the primary treatment used for
ICP [4]. The mother’s ICP symptoms usually resolve
within 48 h of delivery and biochemical abnormalities
resolve within 2–8 weeks [5].
Mutations of several genes may influence the patho-
genesis of ICP [6–13]. In addition, hormonal factors, es-
pecially estrogen and progesterone, may be involved in
the pathogenesis of ICP [14]. Genetic predisposition to
ICP is revealed by family clustering, the presence of
ethnic and geographic variations, and mutations in gene
coding for hepatobiliary transport proteins [1, 14].
Intrahepatic cholestasis has been associated with hepato-
biliary cancers, some autoimmune diseases, and cardio-
vascular diseases [15]. Also increased risk for gestational
diabetes and pre-eclampsia has been reported among
women with a history of ICP [16, 17].
To examine factors influencing causes of death, a long
follow-up is required. Due to the genetic background
and higher occurrence of some diseases, the objective
was to determine whether ICP is associated with causes
of death during on average 35 years follow-up after the
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delivery. To the authors’ knowledge, this is the first
study to investigate this association over such a long
follow-up time.
Methods
Data source and study population
The study population comprised all ICP pregnancies at
Tampere University Hospital (TUH) between 1969 and
1988. Patients with ICP were identified in the hospital
discharge register using diagnosis codes. From 1969 to
1986, ICD-8 was used at TUH. Because ICD-8 did not
include a precise code for ICP, we checked all the obstet-
ric codes that might contain ICP: 637.9 Toxicosis NUD,
639.00 Pruritus, 639.01 Icterus gravis, 639.09 Necrosis
acuta et subacuta hepatis, and 639.98 Aliae definitae.
Thereafter, we checked the written diagnosis behind the
code, and if it referred to ICP, we included the case for
further selection. ICD-9 was used between 1987 and
1988, and it contained the appropriate codes 6467A
Hepatosis gravidarum and 6467X Hepatopathia alia. The
diagnosis was verified from each patient record with the
presence of the main symptom of itching and abnormal
laboratory test results. At least one of the following was
required at that time at Tampere University Hospital:
ASAT > 35 U/l, ALAT > 40 U/l, or bile acids 6 μmol/l or
more. The study population comprised 687 ICP
deliveries.
The study population included some women with re-
peated ICP deliveries, and each of these women were
studied as an individual case. The ICP group thus con-
tained 575 women. Two controls for each ICP delivery
were taken; these controls were the previous and the
next subjects in the maternity ward diary. Altogether,
there were 1374 controls. The groups were comparable
regarding age, educational level, and body mass index
[18]. Four women were ruled out from the ICP cases
because of a missing personal identity code, as were 41
women from the controls. The final cohort comprised
571 women with ICP and 1333 controls. The groups
were comparable regarding the participants’ age at
labour, age at death, and age of those living at the end of
2015 (Table 1).
For the deceased in the cohort, we obtained the under-
lying causes of their death from 1971 to 2015 from Sta-
tistics Finland. The coverage of the underlying cause of
death statistics is practically 100% [19]. The follow-up
time of the cohort’s mothers was 27–46 years. The
causes of death were classified using ICD-10 [20], and
the older ICD-8 and ICD-9 codes were changed to the
corresponding ICD-10 codes.
Statistical analysis
The data were analysed using SPSS for Windows, ver-
sion 22.0. The results are presented as frequencies and
percentages. From cross tabulation, p-values were calcu-
lated using the Chi-squared test, and values of 0.05 or
lower were considered statistically significant. Binary
logistic regression analysis was performed to obtain odds
ratio (OR) and 95% confidence intervals (CI). The
dependent variable was “ICP or not”.
Results
Altogether, 39 of the mothers with ICP (6.8%) and 111
of the controls (8.3%) had died by the end of 2015 (p =
0.267). The underlying causes of death are presented in
Table 2. Each deceased has one underlying cause of
death.
The most common underlying causes of death were
neoplasms, 46% of cases among mothers with ICP and
in 41% of cases among the controls (p = 0.609). There
were no hepatobiliary neoplasms in the ICP group and
only one in the control group. Malignant neoplasms of
digestive system were the underlying causes of death in
28% (n = 5) of ICP women and in 26% (n = 12) of con-
trols (p = 0.890). In the ICP group the malignant neo-
plasms were colon (n = 2), small intestine (n = 1) and
stomach (n = 2) cancers. Respectively, malignant
neoplasms in the control group were pancreas (n = 3),
ampulla of Vater (n = 1), colon (n = 6) and stomach
(n = 2) cancers.
Diseases of the circulatory system were the underlying
cause of death in 13% of cases among mothers with ICP
and in 26% of cases among the controls (p = 0.088). Dis-
eases of the circulatory system were the second common
underlying cause of death among the controls.
Diseases of the digestive system were more often the
underlying cause of death in the ICP group than in the
control group (15% vs. 4%, p = 0.011). The risk to have a
gastrointestinal cause of death was nearly 5-fold in ICP
group compared to controls (OR = 4.85, 95% CI 1.29–
18.18). Diseases of the digestive system were the second
common underlying cause of death among mothers with
Table 1 Median ages of patients at labour, at death, and those still living at the end of 2015
Mothers with ICP Controls
n age age range n age age range
At labour 571 27.6 16.9–41.1 1333 27.1 15.0–46.4
At death 39 56.7 34.1–78.5 111 55.9 28.1–83.8
Living at the end of 2015 532 63.7 48.0–80.8 1222 63.3 46.3–85.0
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ICP. Within gastrointestinal diseases, hepatobiliary
diseases were the underlying cause of death among 67%
(n = 4) of ICP mothers and 75% (n = 3) of controls (p =
0.778). Alcoholic liver diseases were found in four ICP
mothers and in two controls and cirrhosis of liver in one
control. Diseases of pancreas and alcohol-induced
chronic pancreatitis were the underlying causes of death
among two women with ICP. Gastro-oesophageal
laceration-haemorrhage syndrome was the underlying
cause of death in one control. In total, diseases of the
digestive system and malignant neoplasms of the di-
gestive system were the underlying causes of death in
28% (n = 11) of ICP women and 14% (n = 16) of
controls (p = 0.054).
Diseases of the other organ systems were rare in both
groups.
Discussion
The main finding was that women with a history of ICP
do not have an increased overall mortality. There were
more deaths from gastrointestinal diseases in the ICP
group than in the control group. Diseases of the circula-
tory system were twice as frequently the underlying
cause of death in the control group than in the ICP
group.
Strengths and limitations
The data in our study were relevant and the methods
were valid and reliable. One limitation of the study was
the small number of death cases. Nevertheless, the
follow-up time of this study was long, 27–46 years, com-
prising all ICP cases at TUH during the 1969–1988
period. A long follow-up time is required when investi-
gating the causes of death of mothers. Although the
follow-up time was long, the deaths represent those who
died relatively young. Life expectancy of Finnish women
at the age of 65 years was 21 years in 2014 [21]. The life
expectancy of ICP mothers (n = 532) living at the end of
the follow-up in 2015 is over 20 years. An extended
follow-up time would show whether causes of death are
the same for the mothers who die older.
A weakness of the study is that the levels of bile acids
and/or transaminases used for diagnosis of ICP were
somewhat lower than more recent criteria. There is a
possibility of existing liver disease at the time of ICP
diagnosis. However, the diagnosis of ICP requires exclu-
sion of other reasons and the diagnosis was made by an
obstetrician.
Comparison with existing literature
It seems that the mothers with ICP die of cardiovascular
diseases less frequently than expected and the controls
more frequently than expected. The number of deaths
from circulatory diseases seems to be lower in the ICP
group, even though ICP has been associated with circu-
latory diseases [15]. On the other hand, women with
ICP have reported less cardiac arrhythmia, high choles-
terol, and high blood pressure requiring medication [22].
In 2015, diseases of the circulatory system were the
underlying cause of nearly 38% of deaths among Finnish
women over 15 years old [23]. In our study, diseases of
the circulatory system were the underlying cause of
death among 26% of the controls. Our cohort represents
those who died younger, and the proportions of the
causes of death might change if the cohort would be
followed even longer. Although there were fewer deaths
due to diseases of the circulatory system in the ICP
group, it cannot be concluded that ICP protects from
diseases of the circulatory system. ICP has been
associated with gestational diabetes and pre-eclampsia
[16, 17]. Gestational diabetes increases risk of type 2
diabetes, hypertension and ischemic heart disease [24].
An increased risk in cardiovascular diseases have been
associated with pre-eclampsia [25]. Nevertheless, the
mortality to circulatory system diseases was not higher
in our study.
Despite the rather small number of deaths, statistically
significant differences were found. The findings may be
Table 2 Underlying causes of death among women with and without a history of ICP







n % n % % units p-value
Neoplasms (C00–D48) 18 46 46 41 5 0.609
Diseases of the digestive system (K00–K93) 6 15 4 4 11 0.011
External causes of morbidity and mortality, injury, poisoning
and certain consequences of external causes (V01–Y98, S00–T98)
5 13 17 15 -2 0.705
Diseases of the circulatory system (I00–I99) 5 13 29 26 −13 0.088
Endocrine, nutritional and metabolic diseases (E00–E90) 2 5 5 5 0 0.874
Diseases of the nervous system (G00–G99) 2 5 5 5 0 0.874
Diseases of the musculoskeletal system and connective tissue (M00–M99) 1 3 1 1 2 0.420
Diseases of the respiratory system (J00–J99) 0 0 4 4 −4 0.230
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considered clinically relevant. Increased risk of hepato-
biliary diseases has been reported among women who
experience ICP [15, 22, 26, 27]. The increased occur-
rence of hepatobiliary diseases may be reflected in the
increase of deaths from gastrointestinal diseases among
the ICP group.
Hepatobiliary neoplasms as underlying causes of death
were not detected in this study among ICP mothers.
Previously an association between ICP and liver cancer
and biliary tree cancer has been reported [15]. Neverthe-
less, the incidence of these cancers has been found to be
0.1% so that the expected number of these rare cancers
in our cohort is rather low. In this study, we did not
investigate the incidence of different cancers but the
underlying causes of death in the cohort.
Risk consumption of alcohol was not remarkably dif-
ferent among ICP mothers compared to controls in a
questionnaire study of the same cohort [28]. According
to a large Swedish study alcoholic cirrhosis was less
likely to be diagnosed with women with ICP compared
to controls [27]. Alcohol consumption might have an ef-
fect on the underlying causes of death, particularly on
hepatobiliary diseases. Women with a history of ICP
have an increased risk of liver fibrosis and cirrhosis
which might be caused by hepatitis C infection [24].
This finding may reflect on the increased risk of deaths
from gastrointestinal diseases in ICP women.
Many genetic mutations have been found to be associ-
ated with ICP [6–13]. Our hypothesis is that ICP is a
manifestation of a genetic background that exposes the
individual to certain diseases and causes of death.
Conclusion
Women with a history of ICP do not have an increased
overall mortality. However, gastrointestinal diseases are
overrepresented in the underlying causes of death
among women with a history of ICP. This is the first
study to examine the association between ICP and
underlying causes of death over such a long follow-up
time. An even longer follow-up time is required to
investigate further the association between ICP and
gastrointestinal causes of death. This would confirm
whether the phenomenon found in our study continues
among those who die older.
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